STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia - The Lancet Oncology
Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia | NEJM
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation
Schematic representation of the mechanism of action of the BCR-ABLTKIs.... | Download Scientific Diagram
The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL | IntechOpen
Flying under the radar: the new wave of BCR–ABL inhibitors | Nature Reviews Drug Discovery
The tyrosine kinase c-Abl potentiates interferon-mediated antiviral immunity by STAT1 phosphorylation - ScienceDirect
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade | Cell Communication and Signaling | Full Text
IJMS | Free Full-Text | Blockade of Y177 and Nuclear Translocation of Bcr- Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance | Haematologica
Bcr-Abl阻害 | Bcr-Abl Inhibition
Bcr-Abl and Imatinib (STI571 or Gleevec) - Proteopedia, life in 3D
Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics: Cancer Cell
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia | Nature Reviews Cancer
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. - Australian Medical Student Journal
Structure and Dynamic Regulation of Abl Kinases* - ScienceDirect
BCR-ABL signaling mimics growth factor activation. Growth factors are... | Download Scientific Diagram
Dasatinib is an Orally Active Dual Bcr-Abl and Src Family Tyrosine Kinase Inhibitor | MedChemExpress
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia - The Lancet
Mechanism of Action of BCR-ABL and of Its Inhibition by Imatinib. Panel... | Download Scientific Diagram
JCI - Applying the discovery of the Philadelphia chromosome
Frontiers | Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Leukemia
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface* - Journal of Biological Chemistry
